文献速递妇科

Linzagolix治疗子宫内膜异位症相关疼痛的随机临床试验

Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial.
PubMed 文献 · Fertil Steril · 2020-06-04

这项跨国、随机、双盲、安慰剂对照、剂量探索试验评估了口服GnRH拮抗剂linzagolix对子宫内膜异位症相关疼痛的效果。结果显示,75-200mg剂量在12周时显著增加总体盆腔疼痛应答者比例,并改善痛经和非经期盆腔痛,效果维持至24周;骨密度呈剂量依赖性下降,50和75mg剂量24周腰椎平均骨密度丢失<1%。

要点

  • linzagolix 75-200mg每日一次可显著改善子宫内膜异位症相关疼痛。
  • 疗效在24周时维持或增加,生活质量改善且闭经率呈剂量依赖性增加。
  • 骨密度呈剂量依赖性下降,200mg组24周腰椎平均丢失达2.6%。

核心结论

  • Linzagolix在75-200mg剂量下显著减轻子宫内膜异位症相关疼痛并改善生活质量,同时骨密度呈剂量依赖性下降。

研究设计与样本

  • 跨国、平行组、随机、安慰剂对照、双盲、剂量探索试验,纳入18-45岁手术确诊子宫内膜异位症且伴中重度相关疼痛的女性。
  • 干预为linzagolix 50、75、100或200mg或匹配安慰剂每日一次口服,持续24周。
  • 主要终点为12周时总体盆腔疼痛应答者数量(疼痛较基线减少≥30%)。

主要发现

  • 12周时总体盆腔疼痛应答者比例:安慰剂34.5%,75mg组61.5%,100mg组56.4%,200mg组56.3%;≥75mg剂量显著优于安慰剂。
  • 痛经和非经期盆腔痛呈现相似模式,效果在24周时维持或增加。
  • 血清雌二醇受到抑制,生活质量改善,闭经率呈剂量依赖性增加。
  • 24周时腰椎平均骨密度丢失在50和75mg剂量下<1%,200mg剂量下增至2.6%;股骨颈和全髋骨密度呈相似模式。

临床怎么用

  • 对于子宫内膜异位症相关疼痛,可考虑使用linzagolix 75-200mg每日一次,但需监测骨密度变化。
  • 50和75mg剂量对骨密度影响较小(24周腰椎丢失<1%),而200mg剂量骨密度丢失更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the effect of a new investigational oral gonadotropin-releasing hormone antagonist, linzagolix, on endometriosis-associated pain (EAP). DESIGN: A multinational, parallel group, randomized, placebo-controlled, double-blind, dose-ranging trial. SETTING: Clinical centers. PATIENT(S): Women aged 18-45 years with surgically confirmed endometriosis and moderate-to-severe EAP. INTERVENTION(S): The interventions were 50, 75, 100, or 200 mg linzagolix (or matching placebo) administered once daily for 24 weeks. MAIN OUTCOME MEASURE(S): The primary endpoint was the number of responders (≥30% reduction in overall pelvic pain) after 12 weeks. Other endpoints included dysmenorrhea, non-menstrual pelvic pain, serum estradiol, amenorrhea, quality of life (QoL) measures, and bone mineral density (BMD). RESULT(S): Compared with placebo, doses ≥ 75 mg resulted in a significantly greater proportion of responders for overall pelvic pain at 12 weeks (34.5%, 61.5%, 56.4%, and 56.3% for placebo, 75, 100, and 200 mg, respectively). A similar pattern was seen for dysmenorrhea and non-menstrual pelvic pain. The effects were maintained or increased at 24 weeks. Serum estradiol was suppressed, QoL improved, and the rate of amenorrhea increased in a dose-dependent fashion. Mean BMD loss (spine) at 24 weeks was <1% at doses of 50 and 75 mg and increased in a dose-dependent fashion up to 2.6% for 200 mg. BMD of femoral neck and total hip showed a similar pattern. CONCLUSION(S): Linzagolix significantly reduced EAP and improved QoL at doses of 75-200 mg and decreased BMD dose-dependently. CLINICAL TRIAL REGISTRATION NUMBER: NCT02778399.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Donnez J, Taylor HS, Taylor RN, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020. PMID: 32505383. doi:10.1016/j.fertnstert.2020.02.114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。